SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
1-Year Return
71.55%
This Quarter Return
+6.38%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$405M
AUM Growth
+$48.5M
(+14%)
Cap. Flow
+$85.6M
Cap. Flow
% of AUM
21.14%
Top 10 Holdings %
Top 10 Hldgs %
49.16%
Holding
86
New
12
Increased
27
Reduced
11
Closed
19
Top Buys
| 1 |
Nuvalent
NUVL
|
$23.4M |
| 2 |
Erasca
ERAS
|
$17.9M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.8M |
| 4 |
UroGen Pharma
URGN
|
$9.96M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$8.75M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$7.89M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$5.98M |
| 3 |
Perspective Therapeutics
CATX
|
$5.49M |
| 4 |
Praxis Precision Medicines
PRAX
|
$5.1M |
| 5 |
Solid Biosciences
SLDB
|
$4.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Rocket Pharmaceuticals
RCKT
$349M
| – | – |
-101,002
| Closed | -$2.72M |
|
77
Rezolute
RZLT
$642M
| – | – |
-151,985
| Closed | -$388K |
|
78
Scholar Rock
SRRK
$3.12B
| – | – |
-199,415
| Closed | -$3.54M |
|
79
Terns Pharmaceuticals
TERN
$618M
| – | – |
-250,551
| Closed | -$1.64M |
|
80
Viking Therapeutics
VKTX
$2.98B
| – | – |
-20,000
| Closed | -$1.64M |
|
81
Xenon Pharmaceuticals
XENE
$2.98B
| – | – |
-66,090
| Closed | -$2.85M |
|
|
BOLD
82
Boundless Bio
BOLD
$25.3M
| – | – |
-312,500
| Closed | -$4.45M |
|
|
ALPN
83
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-199,020
| Closed | -$7.89M |
|
84
Mineralys Therapeutics
MLYS
$2.2B
| – | – |
-56,944
| Closed | -$735K |
|
85
NewAmsterdam Pharma
NAMS
$2.89B
| – | – |
-99,612
| Closed | -$2.36M |
|
86
Pliant Therapeutics
PLRX
$100M
| – | – |
-183,392
| Closed | -$2.73M |
|